INDIA · WORLD & POLITICS
Dr Reddy’s targets 50–60% cheaper generic Wegovy in India
Economic Times
18 Feb · 12:09 AM
Change
Dr Reddy’s said it is awaiting Indian regulatory approval to sell a generic version of Novo Nordisk’s Wegovy.
Why it matters
Dr Reddy’s publicly set an expected discount range of 50–60% versus Wegovy’s current India list prices, signaling a potential step-change in affordability if the pending approval is granted. That pricing posture can reset reference points for other GLP-1 entrants and for negotiations with distributors and institutional buyers. The company also disclosed it is not currently expanding U.S. manufacturing, which keeps near-term supply scaling tied to existing capacity. Separately, Dr Reddy’s said it is pursuing U.S. approval for a biosimilar rituximab, adding another pending regulatory catalyst in its U.S. portfolio.
Implications
- • India GLP-1 pricing benchmarks may reset if approval is granted
- • Regulatory decision timing becomes the key constraint on market entry
- • Branded Wegovy faces increased price pressure in India
- • Supply scaling depends on existing manufacturing footprint near term
Who is affected
- • Novo Nordisk (Wegovy) India commercial teams
- • Indian obesity/diabetes prescribers and hospital pharmacies
- • Indian drug distributors and institutional buyers/payers
- • Dr Reddy’s Laboratories (GLP-1 and biosimilar portfolio)
Source
Read original → Economic Times
Topics
World & Politics Policy & Regulation Law & Public Safety Regulatory Actions Business & Markets Markets Health & Medicine Pharma & Biotech Healthcare Systems